Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder involving significant social, communication, and behavioral challenges. Behavioral and developmental therapies are the cornerstones of treatment. There is no cure for ASD, and pharmacological intervention is mainly focused on symptomatic treatment of the disease. Risperidone and aripiprazole are the only two FDA-approved treatments to manage the irritability associated with ASD; other drugs are used off-label to manage co-occurring psychological conditions. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for ASD.
Questions answered
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Janssen, Otsuka, Eli Lilly
Key drugs: Aripiprazole, fluoxetine, methylphenidate HCl, risperidone, sertraline
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.